知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

174 条记录 (耗时 0.046 秒)

    ADHESION PROMOTER SYSTEM, AND METHOD OF PRODUCING THE SAME
    3.
    发明申请
    ADHESION PROMOTER SYSTEM, AND METHOD OF PRODUCING THE SAME 审中-公开
    粘合促进剂体系及其生产方法

    公开(公告)号：US20130059165A1

    公开(公告)日：2013-03-07

    申请号：US13697276

    申请日：2011-04-20

    申请人： David L. Malotky ,  Sandra Hofmann ,  Charles F. Diehl ,  Michael D. Read ,  Antonio Batistini ,  H. Craig Silvis ,  Cristiano Betté

    发明人： David L. Malotky ,  Sandra Hofmann ,  Charles F. Diehl ,  Michael D. Read ,  Antonio Batistini ,  H. Craig Silvis ,  Cristiano Betté

    IPC分类号： C09D123/36 ,  B05D5/10 ,  B32B27/32

    CPC分类号： C08L51/00 ,  C08F2438/02 ,  C08L51/003 ,  C08L2205/02 ,  Y10T428/31938 ,  C08L2666/24

    摘要： The instant invention is an adhesion promoter system, and method of producing the same. The adhesion promoter system according to the present invention comprises an aqueous dispersion comprising the melt kneading product of: (a) at least 60 percent by weight of a first functionalized polyolefin, based on the total weight of the solid content; (b) optionally from 0.5 to less than 40 percent by weight of a second functionalized polyolefin, based on the total weight of the solid content, wherein said second functionalized polyolefin comprises homopolymers of propylene or copolymers of propylene with hexene, octene and/or other like alpha-olefins, the homopolymers or copolymers having a single unsaturation, a terminal succinic anhydride moiety, and additional succinic anhydride substitutions on the polypropylene backbone, where the succinic anhydride substitution ranges from about 5 to about 45 weight percent of second functionalized polyolefin; (c) from 0.1 to less than 20 percent by weight of a stabilizing agent, based on the total weight of the solid content; and (d) in the presence of water and optionally one or more neutralizing agents, for example, at a temperature in the range of 25° C. to 200° C.

    摘要翻译： 本发明是一种粘合促进剂体系及其制造方法。 根据本发明的粘合促进剂体系包含水分散体，其包含熔融捏合产物，其基于固体含量的总重量：（a）至少60重量％的第一官能化聚烯烃; （b）基于固体含量的总重量，任选地0.5至小于40重量％的第二官能化聚烯烃，其中所述第二官能化聚烯烃包括丙烯均聚物或丙烯与己烯，辛烯和/或其它物质的共聚物 类似α-烯烃，具有单一不饱和键的均聚物或共聚物，末端琥珀酸酐部分和在聚丙烯主链上的另外的琥珀酸酐取代基，其中琥珀酸酐取代为约5至约45重量％的第二官能化聚烯烃; （c）基于固体含量的总重量，0.1至小于20重量％的稳定剂; 和（d）在水和任选的一种或多种中和剂的存在下，例如在25℃至200℃的温度范围内。

    ADHESION PROMOTER SYSTEM, AND METHOD OF PRODUCING THE SAME
    4.
    发明申请
    ADHESION PROMOTER SYSTEM, AND METHOD OF PRODUCING THE SAME 审中-公开
    粘合促进剂体系及其生产方法

    公开(公告)号：US20130059163A1

    公开(公告)日：2013-03-07

    申请号：US13697262

    申请日：2011-04-20

    申请人： Sandra Hofmann ,  Bart Noordover ,  Cristiano Betté ,  Antonio Batistini ,  Elisa Passaglia ,  H. Craig Silvis

    发明人： Sandra Hofmann ,  Bart Noordover ,  Cristiano Betté ,  Antonio Batistini ,  Elisa Passaglia ,  H. Craig Silvis

    IPC分类号： C09D123/26 ,  B05D5/10 ,  B32B7/12 ,  C09J7/02 ,  B32B27/32

    CPC分类号： C09D123/02 ,  C08L2205/02 ,  C08L2666/24 ,  C09J123/02 ,  Y10T428/31938

    摘要： The instant invention is an adhesion promoter system, and method of producing the same. The adhesion promoter system comprises the admixing product of: (a) at least 60 percent by weight of a first functionalized polyolefin, based on the total weight of the solid content; (b) less than 40 percent by weight of a second functionalized polyolefin, based on the total weight of the solid content, wherein said second functionalized polyolefin comprise homopolymers of propylene or copolymers of propylene with hexene, octene and/or other like alpha-olefins, the homopolymers or copolymers having a single unsaturation, a terminal succinic anhydride moiety, and additional succinic anhydride substitutions on the polypropylene backbone, where the succinic anhydride substitution ranges from about 5 to about 45 weight percent of second functionalized polyolefin; (c) in the presence of one or more solvents.

    摘要翻译： 本发明是一种粘合促进剂体系及其制造方法。 粘合促进剂体系包括以下物质的混合产物：（a）至少60重量％的第一官能化聚烯烃，基于固体含量的总重量; （b）基于固体含量的总重量小于40重量％的第二官能化聚烯烃，其中所述第二官能化聚烯烃包含丙烯的均聚物或丙烯与己烯，辛烯和/或其它类似的α-烯烃的共聚物 ，具有单一不饱和键的均聚物或共聚物，末端琥珀酸酐部分和在聚丙烯主链上的另外的琥珀酸酐取代，其中琥珀酸酐取代为约5至约45重量％的第二官能化聚烯烃; （c）在一种或多种溶剂的存在下。

    Intracorporeal Medicaments for High Energy Phototherapeutic Treatment of Disease
    7.
    发明申请
    Intracorporeal Medicaments for High Energy Phototherapeutic Treatment of Disease 审中-公开
    体内高能量光疗治疗疾病的药物

    公开(公告)号：US20100076246A1

    公开(公告)日：2010-03-25

    申请号：US12543653

    申请日：2009-08-19

    申请人： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

    发明人： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

    IPC分类号： A61N5/10 ,  A61K31/352 ,  A61P35/04

    CPC分类号： A61K31/352 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61K9/0019 ,  A61K41/0038 ,  A61N5/0601 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/1098 ,  C07D311/82

    摘要： New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

    摘要翻译： 描述了新的体内放射碘化物药物和用于治疗人或动物组织的这种高能光疗药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤化呫吨衍生物。 卤化呫吨构成了一种有效的放射增敏剂，其在用电离辐射照射治疗部位时变得光活化。 在本发明的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官的各种病症， 循环系统和相关器官，头颈部，内分泌和淋巴系统及相关器官，各种其他组织，例如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个实施方案中，这些药物是以包括液体，半固体，固体或气溶胶输送载体在内的各种制剂生产的。

    Medicaments for chemotherapeutic treatment of disease
    9.
    发明授权
    Medicaments for chemotherapeutic treatment of disease 失效
    化疗药物治疗疾病

    公开(公告)号：US07648695B2

    公开(公告)日：2010-01-19

    申请号：US09900355

    申请日：2001-07-06

    申请人： H. Craig Dees ,  Timothy C. Scott

    发明人： H. Craig Dees ,  Timothy C. Scott

    IPC分类号： A61K51/00 ,  A61M36/14 ,  G01N33/00

    CPC分类号： A61K41/0057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/193333

    摘要： New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

    摘要翻译： 描述了新的化学治疗药物和用于治疗人或动物组织中的这种化学治疗药物的某些医疗用途和方法，其中这种药物的主要活性成分是卤化呫吨或卤代呫吨衍生物。 优选地，卤代呫吨是玫瑰红或玫瑰红的功能衍生物。 卤代呫吨构成一系列有用的化学治疗剂，其在某些组织中提供选择性的，持续的积累。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物可用于体内或局部给药的各种制剂，包括在液体，半固体，固体或气溶胶输送载体中。